Anti-Human CD3E Recombinant Antibody (Otelixizumab) (CAT#: TAB-H52)

Recombinant Humanized (from rat) antibody to Human CD3E. Otelixizumab, also known as TRX4, is a monoclonal antibody, which is being developed for the treatment of type 1 diabetes and other autoimmune diseases.


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Gene Expression
  • Datasheet
  • MSDS
  • COA

Figure 1 TGF-b is required for the effects of otelixizumab treatment in NOD-huCD3e mice.

Figure 1 TGF-b is required for the effects of otelixizumab treatment in NOD-huCD3e mice.

Treatment with a neutralizing antibody to TGF-b (2G.7) inhibits otelixizumab-induced remission of diabetes inNOD-huCD3e mice(black squares). Anti–TGF-b antibody was administered intraperitoneally (1 mg per injection) on days 1 to 6 after the first otelixizumab administration.

Kuhn, C. , You, S. , Valette, F. , Hale, G. , Van Endert, P. , & Bach, J. F. , et al. (2011). Human cd3 transgenic mice: preclinical testing of antibodies promoting immune tolerance. Science Translational Medicine, 3(68), 68-68.

Figure 2 TGF-b is required for the effects of otelixizumab treatment in NOD-huCD3e mice.

Figure 2 TGF-b is required for the effects of otelixizumab treatment in NOD-huCD3e mice.

Inhibitory effect of recombinant TGF-b (rTGF-b) on in vitro anti-CD3–induced proliferation of CD4+ CD25− T cells from 6-week-old (black circles), diabetic (black squares), or otelixizumab-treated (gray triangles) NOD-huCD3e mice. Data represent mean ± SEM values from three independent experiments. Asterisks indicate significant differences in mean values: **P < 0.01, ***P < 0.001.

Kuhn, C. , You, S. , Valette, F. , Hale, G. , Van Endert, P. , & Bach, J. F. , et al. (2011). Human cd3 transgenic mice: preclinical testing of antibodies promoting immune tolerance. Science Translational Medicine, 3(68), 68-68.

Figure 3 T cells from NOD-huCD3e mice respond to both anti-human and antimouse CD3 antibody stimulation.

Figure 3 T cells from NOD-huCD3e mice respond to both anti-human and antimouse CD3 antibody stimulation.

Apoptotic T cells (7-AAD−annexin V+)(mean ± SEM) as assessed byflow cytometry within splenic CD4+ and CD8+ T cell compartments after a single infection of mitogenic or nonmitogenic anti-mouse [2C11 or F(ab′)2 fragments of 2C11] or anti-human (YTH12.5 or otelixizumab) CD3 antibodies. Results presented are representative of experiments performed on six to eight mice or individual human samples.

Kuhn, C. , You, S. , Valette, F. , Hale, G. , Van Endert, P. , & Bach, J. F. , et al. (2011). Human cd3 transgenic mice: preclinical testing of antibodies promoting immune tolerance. Science Translational Medicine, 3(68), 68-68.

Figure 4 Schematic representation of the humanization strategy for CD3E, CD3D, and CD3G.

Figure 4 Schematic representation of the humanization strategy for CD3E, CD3D, and CD3G.

Representative results of RT-PCR analysis for mouse Cd3 edg or human CD3 EDG expression in the blood cells.

Ueda, O. , Wada, N. A. , Kinoshita, Y. , Hino, H. , Kakefuda, M. , & Ito, T. , et al. (2018). Corrigendum: entire cd3ε, δ, and γ humanized mouse to evaluate human cd3–mediated therapeutics. Scientific Reports, 8, 46960.

Figure 5 Immunohistochemical staining for CD3 in (A) the thymus and (B) the spleen.

Figure 5 Immunohistochemical staining for CD3 in (A) the thymus and (B) the spleen.

The T cell zone in each tissue was specifically stained for CD3 in human CD3 EDG–replaced mice and in wild-type mice. No staining was detected in the tissues of Cd3 edg−/− mice. wt, wild-type mice; mCd3 edg−/−, mouse Cd3 edg knockout mice; hCD3E Tg, human CD3E transgenic mice; 4HH3, 8I12 and 1C3 indicate the three different strains of human CD3 EDG–replaced mice; M, medulla; C, cortex; p< periarteriolar lymphoid sheaths (PALS); F, follicles; R, red pulps; In mCd3 edg−/−, the boundary between cortex (C) and medulla (M) was not clear in either the thymus or the spleen.

Ueda, O. , Wada, N. A. , Kinoshita, Y. , Hino, H. , Kakefuda, M. , & Ito, T. , et al. (2018). Corrigendum: entire cd3ε, δ, and γ humanized mouse to evaluate human cd3–mediated therapeutics. Scientific Reports, 8, 46960.


Specifications

  • Host Species
  • Rat
  • Derivation
  • Humanized (from rat)
  • Type
  • IgG1 - lambda
  • Specificity
  • CD3E (CD3 epsilon) [Homo sapiens]
  • Species Reactivity
  • Human
  • Applications
  • FC, IP, ELISA, Neut, FuncS, IF, WB
  • CAS
  • 881191-44-2
  • Generic Name
  • otelixizumab
  • UNII
  • I5HF2X04PB
  • MW
  • 145.1 kDa
  • Related Disease
  • Psoriasis

Product Property

  • Purity
  • Purity >95% by SDS-PAGE.

Applications

  • Application Notes
  • The CD3E antibody has been reported in applications of Neut, Inhib, FC, RT-PCR, IHC.
    IHC: Monoclonal anti-human CD3 (2.5 μg/mL) was used as a primary antibody for incubation overnight at 4 °C. After incubation with secondary antibody, rat anti-mouse IgG heavy chain (LO-MG1-13: Abcam ab11585), biotin-labelled rabbit anti-rat IgG (5.0 μg/mL), and HRP-labeled streptavidin (5.0 μg/mL) were applied according to the standard ABC method. Tris-HCl buffer with 0.05% 3.3′-diaminobenzidine (DAB) in 0.03% hydrogen peroxide was used for staining.

Target

  • Alternative Names
  • otelixizumab;881191-44-2;TRX4;ChAglyCD3;GSK2136525;TRX4;CD3E;CD3e molecule, epsilon (CD3-TCR complex);CD3e antigen, epsilon polypeptide (TiT3 complex);T-cell surface glycoprotein CD3 epsilon chain;CD3-epsilon;T-cell surface antigen T3/Leu-4 epsilon chain;

Related Resources

  • Biosimilar Overview
Please refer to Otelixizumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Otelixizumab.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Otelixizumab"

Afuco™ Anti-CD3E ADCC Recombinant Antibody (Otelixizumab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant Humanized (from rat) antibody to Human CD3E. Otelixizumab, also known as TRX4, is a monoclonal antibody, which is being developed for the treatment of type 1 diabetes and other autoimmune diseases.

See other products for "CD3E"

Rat Antibody

CAT Product Name Application Type
TAB-H28 Anti-Human CD3E Recombinant Antibody (Ertumaxomab) ELISA, FC, IP, FuncS, IF, Neut, ICC IgG2a / G2b

Humanized Antibody

CAT Product Name Application Type
TAB-714 Anti-CD3E Recombinant Antibody (Visilizumab) FuncS, IF, Neut, ELISA, FC, IP, ICC IgG2
TAB-420CQ Anti-Human CD3E Recombinant Antibody (Visilizumab) ELISA, IHC, FC, IP, IF, FuncS IgG2, κ

Human Antibody

CAT Product Name Application Type
TAB-245 Anti-Human CD3 epsilon Recombinant Antibody (Foralumab) WB, ELISA, FC, IP, FuncS, IF, Neut IgG1 - kappa
TAB-124CL Human Anti-CD3E Recombinant Antibody (TAB-124CL) ELISA Human IgG

Mouse Antibody

Immunotoxin

CAT Product Name Application Type
AGTO-G010E Anti-CD3E immunotoxin UCHT1 (scFv)-PE Cytotoxicity assay, Function study
AGTO-G010D Anti-CD3E immunotoxin UCHT1 (scFv)-DT Cytotoxicity assay, Function study
AGTO-G010R Anti-CD3E immunotoxin UCHT1 (scFv)-RTA Cytotoxicity assay, Function study
AGTO-L049E anti-CD3E immunotoxin UCHT1 (IgG)-PE Cytotoxicity assay, Functional assay
AGTO-L049D anti-CD3E immunotoxin UCHT1 (IgG)-DT Cytotoxicity assay, Functional assay

Rabbit Monoclonal Antibody

ADCC Enhanced Antibody

CAT Product Name Application Type
AFC-TAB-245 Afuco™ Anti-CD3E ADCC Recombinant Antibody (Foralumab), ADCC Enhanced ELISA, FC, IP, FuncS, IF ADCC enhanced antibody
AFC-TAB-H52 Afuco™ Anti-CD3E ADCC Recombinant Antibody (Otelixizumab), ADCC Enhanced FC, IP, ELISA, Neut, FuncS, IF ADCC enhanced antibody
AFC-TAB-714 Afuco™ Anti-CD3E ADCC Recombinant Antibody (Visilizumab), ADCC Enhanced FuncS, IF, Neut, ELISA, FC, IP ADCC enhanced antibody
AFC-TAB-019 Afuco™ Anti-CD3E ADCC Recombinant Antibody (Muromonab-Cd3), ADCC Enhanced FC, IP, ELISA, Neut, FuncS, IF ADCC enhanced antibody

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for TAB-H52. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare